Fidelity International
XLO icon

Fidelity International’s Xilio Therapeutics XLO Stock Holding History

Fidelity International’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,622
Closed -$209K – 976
2024
Q4 		$209K Hold
15,622
– – ﹤0.01% 822
2024
Q3 		$172K Hold
15,622
– – ﹤0.01% 831
2024
Q2 		$207K Hold
15,622
– – ﹤0.01% 790
2024
Q1 		$236K Hold
15,622
– – ﹤0.01% 791
2023
Q4 		$120K Hold
15,622
– – ﹤0.01% 767
2023
Q3 		$461K Hold
15,622
– – ﹤0.01% 723
2023
Q2 		$573K Hold
15,622
– – ﹤0.01% 710
2023
Q1 		$695K Hold
15,622
– – ﹤0.01% 732
2022
Q4 		$588K Hold
15,622
– – ﹤0.01% 733
2022
Q3 		$636K Hold
15,622
– – ﹤0.01% 738
2022
Q2 		$639K Hold
15,622
– – ﹤0.01% 742
2022
Q1 		$1.55M Hold
15,622
– – ﹤0.01% 706
2021
Q4 		$3.5M Buy
+15,622
New +$3.72M ﹤0.01% 641

Other funds holding XLO

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Fidelity International's XLO Position: Q1 2025 in Review

Fidelity International sold out of Xilio Therapeutics (XLO) in Q1 2025, closing a stake of 15,622 shares — an estimated $209K sold.

Fidelity International first reported a position in XLO in Q4 2021 and held it in 13 quarters. The position peaked at $3.5M in Q4 2021. 35 funds tracked by Wall St. Rank hold XLO as of Q1 2025.

  • Fidelity International reported no remaining Xilio Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Fidelity International sold 15,622 Xilio Therapeutics shares in Q1 2025, an estimated $209K.
  • Fidelity International first reported a position in Xilio Therapeutics in Q4 2021 and held it in 13 quarters.
  • Fidelity International's Xilio Therapeutics position peaked at $3.5M in Q4 2021.
  • 35 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2025.

Based on Fidelity International's 13F filing for Q1 2025, filed 12 May 2025.